Pediatric acute myeloid leukemia with t(8;16)(p11;p13): a distinct clinical and biological
entity: results of a collaborative study by the international Berlin-Frankfurt-Münster AML Study …

… the biology and genetics of AML, the results of recent clinical … with acute megakaryoblastic
leukemia, those with inv(16)(p13… (10;11)(p12;q23) and t(10;11)(p11.2;q23) have high rates of …

… Pediatric acute myeloid leukemia with t(8;16)(p11;p13), a distinct clinical and biological entity:
a collaborative study by the International-Berlin-Frankfurt-Munster AML-study group. Blood…

… /infant leukemia accounts for <1% of all childhood leukemias. When … study groups (International
Berlin-Frankfurt-Münster … , characteristic for infant AML, are t(1;22)(p13.3;q13.1)/RBM15-…

… driving current therapies and upcoming clinical trials. … Similarly, myeloid leukemia of Down's
syndrome is a unique … Thus, pediatric cooperative groups remain divided on cytarabine …

… AML without known type 2 aberrations using routine clinical diagnostics, which varied
among the participating collaborative groups in this study as they all used a slightly different …

… alterations involving CREBBP in pediatric patients with AML … ) and associated with
comprehensive clinical and cytogenetic … of acute myeloid leukemia with translocation t(8;16)(p11;p13…

… Pediatric acute myeloid leukemia with t(8;16)(p11;p13), a distinct clinical and biological entity:
a collaborative study by the International-Berlin-Frankfurt-Munster AML-study group. Blood…

… Decades of coordinated efforts through cooperative group … with unique clinical
characteristics such as leukemia cutis, … The fusion of ETV6 with MNX1, resulting from t(7;12)(q36;p13), …

… In conclusion, cytogenetic subtypes of pediatric AML have distinct … used methods, which
limits its clinical applicability. We believe that the … (7;12)(q36;p13), t(8;16)(p11;p13), and NUP98-…